buthionine sulfoximine has been researched along with Neoplasms in 43 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 8 (18.60) | 18.7374 |
| 1990's | 10 (23.26) | 18.2507 |
| 2000's | 9 (20.93) | 29.6817 |
| 2010's | 10 (23.26) | 24.3611 |
| 2020's | 6 (13.95) | 2.80 |
| Authors | Studies |
|---|---|
| Bellows, DS; Clarke, ID; Diamandis, P; Dirks, PB; Graham, J; Jamieson, LG; Ling, EK; Sacher, AG; Tyers, M; Ward, RJ; Wildenhain, J | 1 |
| Jia, Q; Li, J; Qiao, C; Wang, X; Wang, Z; Xiao, H; Yang, Y; Yang, Z; Yu, J; Zhang, R; Zhou, B | 1 |
| Chen, Z; Jia, Q; Liu, X; Pu, K; Qiao, C; Wang, X; Wang, Z; Yang, Z; Zhang, R | 1 |
| Anraku, Y; Ikoma, T; Nakagawa, Y; Quindoza, GM | 1 |
| Jia, Q; Liu, G; Liu, X; Ning, P; Qiao, C; Rao, Z; Wang, L; Wang, Z; Xia, Y; Yang, P; Zhang, R; Zhang, X; Zhu, Y | 1 |
| Barros Ibiapina, A; Carneiro da Silva, FC; de Castro E Sousa, JM; Dos Reis Oliveira, C; Ferreira, PMP; Pereira, JC; Roseno Martins, IR | 1 |
| Gong, S; Hu, Y; Lu, M; Luo, Y; Ma, XN; Tian, J; Wu, Y; Xu, Z; Yu, BY; Yu, XA; Zhang, Y | 1 |
| De Ridder, M; Jiang, H; Wang, H | 1 |
| Floberg, JM; Schwarz, JK | 1 |
| Jung, CL; Kim, HJ; Kim, JS; Kong, AN; Lee, CH; Park, JH | 1 |
| Aldrich-Wright, JR; Garbutcheon-Singh, KB; Harper, BW; Myers, S | 1 |
| Boix, J; Mattiolo, P; Ribas, J | 1 |
| Dvořák, Z; Kašpárková, J; Prachařová, J; Radošová-Muchová, T; Štarha, P; Trávníček, Z; Vančo, J | 1 |
| Kuppusamy, P; Rivera, BK; Vikram, DS | 1 |
| Akitaya, T; Kamiie, K; Kidachi, Y; Noshita, T; Ryoyama, K; Umetsu, H; Yamaguchi, H; Yoshida, K; Yu, T | 1 |
| Aykin-Burns, N; Coleman, MC; Dayal, D; Domann, FE; Owens, KM; Spitz, DR | 1 |
| Ardail, D; Beuve, M; Boivin, A; Colliaux, A; Douki, T; Foray, N; Hanot, M; Malésys, C; Rodriguez-Lafrasse, C | 1 |
| Batist, G; Fotouhi-Ardakani, N; Hamilton, D | 1 |
| Hori, S; Kakehi, Y; Kakizuka, A; Maeda, H; Ogawa, O; Ohizumi, H; Segawa, T | 1 |
| Renschler, MF | 1 |
| Barbacioru, C; Dai, Z; Huang, Y; Sadée, W | 1 |
| Engel, RH; Evens, AM | 1 |
| Estrela, JM; Obrador, E; Ortega, A | 1 |
| Giovannini, C; Grande, S; Guidoni, L; Luciani, AM; Palma, A; Rosi, A; Sapora, O; Viti, V | 1 |
| Adams, GE | 1 |
| Brennan, J; Gallo, JM; Halbherr, T; Hamilton, TC; Laub, PB; O'Dwyer, PJ; Ozols, RF | 1 |
| Eady, JJ; Orta, T; Peacock, JH; Steel, GG | 1 |
| Godwin, AK; Hamilton, TC; O'Dwyer, PJ; Ozols, RF; Yao, K | 1 |
| Alberti, D; Arzoomanian, RZ; Bailey, HH; Mulcahy, RT; Pomplun, M; Spriggs, DR; Tombes, MB; Tutsch, KD; Wilding, G | 1 |
| Bookman, MA; Brennan, J; Comis, RL; Gallo, JM; Halbherr, T; Hamilton, TC; Hoffman, J; Kilpatrick, D; LaCreta, FP; O'Dwyer, PJ; Ozols, RF; Young, RC | 1 |
| Alberti, D; Arzoomanian, RZ; Bailey, HH; Feierabend, C; Mahvi, D; Mulcahy, RT; Pomplun, M; Ripple, G; Schink, J; Tutsch, KD; Wilding, G | 1 |
| Calvert, P; Hamilton, TC; O'Dwyer, PJ; Yao, KS | 1 |
| Bailey, HH | 1 |
| Batist, G; Carystinos, GD; Chen, X | 1 |
| Carp, N; Comis, RL; Hamilton, TC; LaCreta, FP; O'Dwyer, PJ; Ozols, RF; Padavic, K; Tew, KD; Young, RC | 1 |
| DeGraff, W; Friedman, N; Mitchell, JB; Russo, A | 1 |
| Cook, JA; DeGraff, W; Glatstein, E; Mitchell, JB; Russo, A | 1 |
| Evans, WK; Stewart, DJ | 1 |
| Glatstein, E; Kinsella, TJ; Mitchell, JB; Russo, A | 1 |
| Dorr, RT; Liddil, JD; Soble, MJ | 1 |
| Guichard, M; Lespinasse, F; Malaise, EP | 1 |
| Astromoff, A; Harris, JW; Li, GC; Shrieve, DC | 1 |
| Chew, EH; Holmgren, A; Lu, J | 1 |
12 review(s) available for buthionine sulfoximine and Neoplasms
| Article | Year |
|---|---|
Buthionine sulfoximine and chemoresistance in cancer treatments: a systematic review with meta-analysis of preclinical studies.
Topics: Antineoplastic Agents; Buthionine Sulfoximine; Drug Resistance, Neoplasm; Humans; Methionine Sulfoximine; Neoplasms | 2023 |
Targeting antioxidant enzymes as a radiosensitizing strategy.
Topics: Antioxidants; Buthionine Sulfoximine; Glutathione; Homeostasis; Humans; Models, Biological; Neoplasms; Radiation-Sensitizing Agents; Reactive Oxygen Species; Superoxide Dismutase | 2018 |
Manipulation of Glucose and Hydroperoxide Metabolism to Improve Radiation Response.
Topics: Animals; Auranofin; Buthionine Sulfoximine; Deoxyglucose; Glucose; Glycolysis; Humans; Hydrogen Peroxide; Neoplasms; Oxidation-Reduction; Oxidative Stress; Radiation-Sensitizing Agents | 2019 |
The glutathione system in alkylator resistance.
Topics: Alkylating Agents; Anticarcinogenic Agents; Buthionine Sulfoximine; Enzyme Inhibitors; Ethacrynic Acid; Glutamate-Cysteine Ligase; Glutathione; Glutathione Synthase; Humans; Neoplasms; Pyrazines; Thiones; Thiophenes | 2002 |
The emerging role of reactive oxygen species in cancer therapy.
Topics: Antineoplastic Agents; Buthionine Sulfoximine; Combined Modality Therapy; DNA; Humans; Metalloporphyrins; Neoplasms; Oxidation-Reduction; Procarbazine; Reactive Oxygen Species | 2004 |
Oxidative stress and apoptosis: a new treatment paradigm in cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Buthionine Sulfoximine; Cell Death; Dose-Response Relationship, Drug; Glutathione; Hexanones; Humans; Metalloporphyrins; Models, Biological; Models, Chemical; Neoplasms; Oxidation-Reduction; Oxidative Stress; Oxides; Reactive Oxygen Species | 2006 |
Glutathione in cancer biology and therapy.
Topics: Animals; Apoptosis; Buthionine Sulfoximine; Genes, bcl-2; Glutathione; Humans; Neoplasm Metastasis; Neoplasms | 2006 |
Clinical studies of reversal of drug resistance based on glutathione.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Buthionine Sulfoximine; Clinical Trials as Topic; Drug Resistance; Female; Glutathione; Humans; Male; Melphalan; Neoplasms | 1998 |
Potential for selective modulation of glutathione in cancer chemotherapy.
Topics: Animals; Buthionine Sulfoximine; Cell Communication; Drug Resistance; Enzyme Inhibitors; Female; Gap Junctions; Glutamate-Cysteine Ligase; Glutathione; Humans; Mammary Neoplasms, Experimental; Neoplasms; Prodrugs; Pyroglutamate Hydrolase; Pyrrolidonecarboxylic Acid; Rats; Thiazoles; Thiazolidines | 1998 |
Glutathione modulation in cancer treatment: will it work?
Topics: Antineoplastic Agents; Buthionine Sulfoximine; Cell Line; Glutathione; Humans; Methionine Sulfoximine; Neoplasms; Radiation-Sensitizing Agents | 1989 |
Non-chemotherapeutic agents that potentiate chemotherapy efficacy.
Topics: Adult; Amphotericin B; Animals; Antimetabolites; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Buthionine Sulfoximine; Calcium Channel Blockers; Calmodulin; Cardiotonic Agents; Child; Clinical Trials as Topic; Dipyridamole; Drug Evaluation; Drug Resistance; Drug Synergism; Drug Therapy, Combination; Female; Humans; Ketoconazole; Male; Methionine Sulfoximine; Mice; Neoplasms; Nitroimidazoles; Xanthines | 1989 |
The use of non-hypoxic cell sensitizers in radiobiology and radiotherapy.
Topics: Animals; Bromodeoxyuridine; Buthionine Sulfoximine; Cell Survival; Cricetinae; Diamide; DNA Repair; Glutathione; Humans; Idoxuridine; In Vitro Techniques; Methionine Sulfoximine; Neoplasms; Radiation-Sensitizing Agents | 1986 |
6 trial(s) available for buthionine sulfoximine and Neoplasms
| Article | Year |
|---|---|
Time-dependent pharmacodynamic models in cancer chemotherapy: population pharmacodynamic model for glutathione depletion following modulation by buthionine sulfoximine (BSO) in a Phase I trial of melphalan and BSO.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Buthionine Sulfoximine; Enzyme Inhibitors; Glutathione; Humans; Melphalan; Methionine Sulfoximine; Neoplasms; Neutrophils | 1995 |
Variable baseline gamma-glutamylcysteine synthetase messenger RNA expression in peripheral mononuclear cells of cancer patients, and its induction by buthionine sulfoximine treatment.
Topics: Adult; Antimetabolites, Antineoplastic; Base Sequence; Buthionine Sulfoximine; Dose-Response Relationship, Drug; Enzyme Induction; Female; Glutamate-Cysteine Ligase; Humans; Male; Methionine Sulfoximine; Molecular Sequence Data; Neoplasms; Polymerase Chain Reaction; RNA, Messenger | 1993 |
Phase I clinical trial of intravenous L-buthionine sulfoximine and melphalan: an attempt at modulation of glutathione.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Buthionine Sulfoximine; Female; Glutathione; Humans; Infusions, Intravenous; Male; Melphalan; Methionine Sulfoximine; Middle Aged; Neoplasms | 1994 |
Phase I trial of buthionine sulfoximine in combination with melphalan in patients with cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Buthionine Sulfoximine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Glutathione; Humans; Linear Models; Male; Melphalan; Methionine Sulfoximine; Middle Aged; Nausea; Neoplasm Recurrence, Local; Neoplasms; Neutropenia; Neutrophils; Radiography; Vomiting | 1996 |
Phase I study of continuous-infusion L-S,R-buthionine sulfoximine with intravenous melphalan.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Buthionine Sulfoximine; Drug Administration Schedule; Female; Glutathione; Humans; Infusions, Intravenous; Lymphocytes; Male; Melphalan; Middle Aged; Neoplasms; Treatment Outcome | 1997 |
Non-chemotherapeutic agents that potentiate chemotherapy efficacy.
Topics: Adult; Amphotericin B; Animals; Antimetabolites; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Buthionine Sulfoximine; Calcium Channel Blockers; Calmodulin; Cardiotonic Agents; Child; Clinical Trials as Topic; Dipyridamole; Drug Evaluation; Drug Resistance; Drug Synergism; Drug Therapy, Combination; Female; Humans; Ketoconazole; Male; Methionine Sulfoximine; Mice; Neoplasms; Nitroimidazoles; Xanthines | 1989 |
26 other study(ies) available for buthionine sulfoximine and Neoplasms
| Article | Year |
|---|---|
Chemical genetics reveals a complex functional ground state of neural stem cells.
Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutical Preparations; Sensitivity and Specificity; Stem Cells | 2007 |
A Potent Strategy of Combinational Blow Toward Enhanced Cancer Chemo-Photodynamic Therapy via Sustainable GSH Elimination.
Topics: Buthionine Sulfoximine; Glutathione; Humans; Neoplasms; Photochemotherapy; Reactive Oxygen Species | 2022 |
Redox dyshomeostasis modulation of the tumor intracellular environment through a metabolic intervention strategy for enhanced photodynamic therapy.
Topics: Buthionine Sulfoximine; Cell Line, Tumor; Glutathione; Humans; Hypoxia; Lipids; Metal-Organic Frameworks; Metformin; Neoplasms; Oxidation-Reduction; Photochemotherapy; Photosensitizing Agents; Singlet Oxygen | 2022 |
Adsorption of l-buthionine sulfoximine on Bi(III) and Eu(III) co-substituted hydroxyapatite nanocrystals for enhancing radiosensitization effects.
Topics: Adsorption; Buthionine Sulfoximine; Durapatite; Glutathione; Humans; Ions; Methionine Sulfoximine; Nanoparticles; Neoplasms | 2023 |
Iron-based metal-organic framework co-loaded with buthionine sulfoximine and oxaliplatin for enhanced cancer chemo-ferrotherapy via sustainable glutathione elimination.
Topics: Animals; Buthionine Sulfoximine; Glutathione; Humans; Metal-Organic Frameworks; Mice; Neoplasms; Oxaliplatin | 2023 |
A cancer-specific activatable theranostic nanodrug for enhanced therapeutic efficacy via amplification of oxidative stress.
Topics: Animals; Artemisinins; Buthionine Sulfoximine; Drug Carriers; Female; Glutathione; Hep G2 Cells; Humans; Liposomes; Mice; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; Neoplasms; Oxidation-Reduction; Oxidative Stress; Precision Medicine; Reactive Oxygen Species; Transferrin | 2020 |
Synergistic activation of the Nrf2-signaling pathway by glyceollins under oxidative stress induced by glutathione depletion.
Topics: Animals; Anticarcinogenic Agents; Antioxidants; Buthionine Sulfoximine; Cell Line; Genes, Reporter; Glutamate-Cysteine Ligase; Glutathione; Glycine max; Hep G2 Cells; Humans; Hypoxia-Inducible Factor-Proline Dioxygenases; Mice; Neoplasms; NF-E2-Related Factor 2; Oxidative Stress; Phytochemicals; Pterocarpans; Signal Transduction | 2013 |
Combination studies of platinum(II)-based metallointercalators with buthionine-S,R-sulfoximine, 3-bromopyruvate, cisplatin or carboplatin.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Buthionine Sulfoximine; Carboplatin; Cell Line; Cell Line, Tumor; Cell Survival; Cisplatin; Dose-Response Relationship, Drug; Drug Synergism; Glutathione; Humans; Inhibitory Concentration 50; Molecular Structure; Neoplasms; Organoplatinum Compounds; Platinum; Pyruvates | 2014 |
Pharmacological modulation of reactive oxygen species in cancer treatment.
Topics: Antineoplastic Agents; Buthionine Sulfoximine; Drug Discovery; Gene Expression Regulation, Neoplastic; Humans; Mitochondrial Dynamics; Neoplasms; Oxidative Stress; Reactive Oxygen Species; Sulfonamides; Tumor Suppressor Protein p53 | 2015 |
Potentiating effect of UVA irradiation on anticancer activity of Carboplatin derivatives involving 7-azaindoles.
Topics: Antineoplastic Agents; Buthionine Sulfoximine; Carboplatin; Cell Line, Tumor; Cell Survival; DNA Adducts; DNA Breaks, Double-Stranded; Drug Synergism; Humans; Indoles; Molecular Structure; Neoplasms; Nucleic Acid Conformation; Proton Magnetic Resonance Spectroscopy; Spectrometry, Mass, Electrospray Ionization; Ultraviolet Rays | 2015 |
In vivo imaging of free radicals and oxygen.
Topics: Animals; Antimetabolites, Antineoplastic; Brain; Buthionine Sulfoximine; Carbon Dioxide; Electron Spin Resonance Spectroscopy; Female; Free Radicals; Humans; Hypoxia; Image Processing, Computer-Assisted; Molecular Structure; Myocardial Contraction; Myocardial Reperfusion Injury; Myocardium; Neoplasms; Nitric Oxide; Oxidation-Reduction; Oximetry; Oxygen; Radiation-Sensitizing Agents; Rats; Rats, Sprague-Dawley; Skin | 2010 |
Selective toxicity of glycyrrhetinic acid against tumorigenic r/m HM-SFME-1 cells is potentially attributed to downregulation of glutathione.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 2; Acetylcysteine; Animals; Anti-Inflammatory Agents; Buthionine Sulfoximine; Cell Line; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Down-Regulation; Free Radical Scavengers; Glutathione; Glycyrrhetinic Acid; Inhibitory Concentration 50; Models, Molecular; Molecular Conformation; Neoplasms; Oxidation-Reduction; Protein Binding; Protein Conformation; Reactive Oxygen Species; Up-Regulation | 2011 |
Genomic instability induced by mutant succinate dehydrogenase subunit D (SDHD) is mediated by O2(-•) and H2O2.
Topics: Animals; Buthionine Sulfoximine; Catalase; Cell Transformation, Neoplastic; Cricetinae; Fibroblasts; Gene Expression; Genomic Instability; Glutathione; Humans; Hydrogen Peroxide; Mutagenesis, Site-Directed; Mutation Rate; Neoplasms; Plasmids; Point Mutation; Polyethylene Glycols; Protein Subunits; Succinate Dehydrogenase; Superoxide Dismutase; Superoxides; Transfection | 2012 |
Glutathione depletion and carbon ion radiation potentiate clustered DNA lesions, cell death and prevent chromosomal changes in cancer cells progeny.
Topics: Buthionine Sulfoximine; Carbon; Cell Cycle Checkpoints; Cell Death; Cell Line, Tumor; Cell Survival; Chromatography, High Pressure Liquid; Chromosomes, Human; Clone Cells; Cluster Analysis; Dimethyl Fumarate; DNA Breaks, Double-Stranded; DNA Breaks, Single-Stranded; DNA Damage; Fumarates; Gene Rearrangement; Glutathione; Histones; Humans; Ions; Kinetics; Micronucleus Tests; Neoplasms; Radiation; X-Rays | 2012 |
Effective treatment of advanced solid tumors by the combination of arsenic trioxide and L-buthionine-sulfoximine.
Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Buthionine Sulfoximine; Cell Division; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Interactions; Drug Resistance, Neoplasm; Drug Therapy, Combination; Female; Glutathione; HeLa Cells; Humans; Hydrogen Peroxide; Male; Mice; Neoplasm Metastasis; Neoplasm Transplantation; Neoplasms; Oxides; Prostatic Neoplasms; Reactive Oxygen Species; Transplantation, Heterologous; Xenograft Model Antitumor Assays | 2004 |
Cystine-glutamate transporter SLC7A11 in cancer chemosensitivity and chemoresistance.
Topics: Amino Acid Transport System y+; Antimetabolites, Antineoplastic; Buthionine Sulfoximine; Cell Line, Tumor; Cystine; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Glutathione; Humans; Neoplasms; RNA, Small Interfering | 2005 |
Metabolism of glutathione in tumour cells as evidenced by 1H MRS.
Topics: Buthionine Sulfoximine; Cell Line, Tumor; Cysteine; Glutamic Acid; Glutathione; Humans; Magnetic Resonance Spectroscopy; Neoplasms; Protons; Time Factors | 2007 |
Radiosensitizers: a conference preview.
Topics: Animals; Aziridines; Buthionine Sulfoximine; Carmustine; Combined Modality Therapy; Drug Synergism; Etanidazole; Humans; Ketones; Lomustine; Maleates; Methionine Sulfoximine; Mice; Misonidazole; Neoplasms; Nitroimidazoles; Radiation-Sensitizing Agents | 1984 |
Glutathione manipulation and the radiosensitivity of human tumour and fibroblast cell lines.
Topics: Buthionine Sulfoximine; Fibroblasts; Glutathione; Humans; Methionine Sulfoximine; Neoplasms; Radiation Tolerance; Tumor Cells, Cultured | 1995 |
L-S,R-buthionine sulfoximine: historical development and clinical issues.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Buthionine Sulfoximine; Drug Resistance; Enzyme Inhibitors; Female; Glutamate-Cysteine Ligase; History, 20th Century; Humans; Male; Melphalan; Neoplasms | 1998 |
Depletion of glutathione in normal and malignant human cells in vivo by buthionine sulfoximine: clinical and biochemical results.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Buthionine Sulfoximine; Female; Glutathione; Humans; Melphalan; Methionine Sulfoximine; Middle Aged; Neoplasms | 1992 |
Selective modulation of glutathione levels in human normal versus tumor cells and subsequent differential response to chemotherapy drugs.
Topics: Antineoplastic Agents; Bleomycin; Buthionine Sulfoximine; Cell Survival; Cells, Cultured; Cisplatin; Glutathione; Humans; Lung; Lung Neoplasms; Melphalan; Methionine Sulfoximine; Neoplasms; Pyrrolidonecarboxylic Acid; Thiazoles; Thiazolidines; Zinostatin | 1986 |
Cytotoxic effects of glutathione synthesis inhibition by L-buthionine-(SR)-sulfoximine on human and murine tumor cells.
Topics: Animals; Antineoplastic Agents; Buthionine Sulfoximine; Cell Line; Cell Survival; Female; Glutathione; Humans; Male; Melphalan; Methionine Sulfoximine; Mice; Mice, Inbred BALB C; Mice, Inbred DBA; Neoplasms; Sulfhydryl Compounds | 1986 |
Influence of buthionine sulfoximine and misonidazole on glutathione level and radiosensitivity of human tumor xenografts.
Topics: Adenocarcinoma; Animals; Buthionine Sulfoximine; Cell Line; Colonic Neoplasms; Female; Glutathione; Humans; Melanoma; Methionine Sulfoximine; Mice; Mice, Nude; Misonidazole; Neoplasm Transplantation; Neoplasms; Radiation Tolerance; Transplantation, Heterologous | 1986 |
Cellular glutathione, thermal sensitivity, and thermotolerance in Chinese hamster fibroblasts and their heat-resistant variants.
Topics: Animals; Buthionine Sulfoximine; Cell Line; Cell Survival; Cricetinae; Cricetulus; Fibroblasts; Glutathione; Hot Temperature; Hyperthermia, Induced; Methionine Sulfoximine; Neoplasms; Time Factors | 1986 |
Targeting thioredoxin reductase is a basis for cancer therapy by arsenic trioxide.
Topics: Amino Acid Sequence; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cell Survival; Enzyme Inhibitors; Glutathione; Humans; Molecular Sequence Data; Neoplasms; Oxidation-Reduction; Oxides; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Thioredoxin-Disulfide Reductase | 2007 |